FDA actions in brief
Sodium phosphate monobasic monohydrate/sodium phosphate dibasic anhydrous tablets (OsmoPrep, Salix) were approved by FDA for cleansing of the colon prior to colonoscopy in patients aged 18 years or older.
Sodium phosphate monobasic monohydrate/sodium phosphate dibasic anhydrous tablets (OsmoPrep, Salix) were approved by FDA for cleansing of the colon prior to colonoscopy in patients aged 18 years or older.
FDA approved omeprazole/sodium bicarbonate (Zegerid, Santarus), an immediate-release proton pump inhibitor (PPI), for the short-term treatment of active duodenal ulcers and erosive esophagitis diagnosed by endoscopy, the short-term treatment of active benign gastric ulcers, the maintenance of healing of erosive esophagitis, and for heartburn and other symptoms associated with gastroesophageal reflux disease (GERD).
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
